New RNA therapy tested for Tough-to-Treat autoimmune conditions
NCT ID NCT07322718
Summary
This early-stage study is testing the safety and initial effectiveness of a new treatment called RXIM002 for adults with severe autoimmune diseases that have returned or not improved with standard therapies. RXIM002 is an experimental RNA-based therapy designed to modify a patient's own immune cells to target disease-causing B cells. The study will enroll 27 participants with conditions like lupus, scleroderma, and autoimmune blood disorders to monitor side effects and see if the treatment helps control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B CELL-MEDIATED AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Huangpu District, No. 197, Ruijin 2nd Road, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.